Literature DB >> 14760915

Mechanisms of termination of atrial fibrillation by Class I antiarrhythmic drugs: evidence from clinical, experimental, and mathematical modeling studies.

Stanley Nattel1, James Kneller, Renqiang Zou, L Joshua Leon.   

Abstract

Sodium channel blocking drugs (Class I antiarrhythmic agents) have been used for the termination of atrial fibrillation (AF) and for sinus rhythm maintenance for almost 100 years. Despite this long history, the mechanisms that underlie their efficacy in AF remain poorly understood. Classic notions about the determinants of cardiac reentry, as embodied in leading circle theory, and of AF, as reflected in the multiple wavelet hypothesis, suggest that cardiac conduction slowing should promote, rather than prevent, AF. This article reviews the evidence (both clinical and experimental) for the efficacy and mechanisms of action of Class I antiarrhythmic agents in AF. Application of mathematical models of AF to the evaluation of Class I mechanisms is discussed, and recent insights into the latter are presented. A better understanding of the ways in which Na+ channel blockers affect AF will be useful, not only for new antiarrhythmic drug development but also for gaining insight into the mechanisms of the arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14760915     DOI: 10.1046/j.1540.8167.90302.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  11 in total

1.  In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.

Authors:  Martin Aguilar-Shardonofsky; Edward J Vigmond; Stanley Nattel; Philippe Comtois
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Nonlinear and Stochastic Dynamics in the Heart.

Authors:  Zhilin Qu; Gang Hu; Alan Garfinkel; James N Weiss
Journal:  Phys Rep       Date:  2014-10-10       Impact factor: 25.600

Review 3.  Pharmacological cardioversion of atrial fibrillation: current management and treatment options.

Authors:  Giuseppe Boriani; Igor Diemberger; Mauro Biffi; Cristian Martignani; Angelo Branzi
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

5.  Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Brittany Gianetti; Andrew C Zygmunt; Jonathan M Cordeiro; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

6.  Pro- and antiarrhythmic effects of ATP-sensitive potassium current activation on reentry during early afterdepolarization-mediated arrhythmias.

Authors:  Marvin G Chang; Enno de Lange; Guillaume Calmettes; Alan Garfinkel; Zhilin Qu; James N Weiss
Journal:  Heart Rhythm       Date:  2012-12-12       Impact factor: 6.343

7.  Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Aaron Glass; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-03-21       Impact factor: 6.343

8.  Inhibitory effects of tetrandrine on the Na(+) channel of human atrial fibrillation myocardium.

Authors:  Li Chen; Qi-Yong Li; Yan Yang; Zhong-Wen Li; Xiao-Rong Zeng
Journal:  Acta Pharmacol Sin       Date:  2009-01-19       Impact factor: 6.150

9.  Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.

Authors:  Dan Hu; Hector Barajas-Martínez; Alexander Burashnikov; Brian K Panama; Jonathan M Cordeiro; Charles Antzelevitch
Journal:  Int J Cardiol       Date:  2016-01-07       Impact factor: 4.164

10.  Bi-atrial high-density mapping reveals inhibition of wavefront turning and reduction of complex propagation patterns as main antiarrhythmic mechanisms of vernakalant.

Authors:  Arne van Hunnik; Stef Zeemering; Piotr Podziemski; Pawel Kuklik; Marion Kuiper; Sander Verheule; Ulrich Schotten
Journal:  Europace       Date:  2021-07-18       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.